[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602151":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":12,"locations":7,"responsibleParty":18,"collaborators":7,"id":20,"slug":21,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":7,"acronym":7,"eligibilityCriteria":7,"healthyVolunteers":22,"sex":7,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":25,"phases":7,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":37,"whyStopped":7,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":42,"locationsCount":7},{"fullName":5,"class":6},"AMO Pharma Limited","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Tideglusib",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Harriet Gray-Stephens, BM BCh, MA (Oxon), MFPM","CONTACT","+44 (0)1270 270010","h.graystephens@amo-pharma.com",{"type":19,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100602151","tideglusib-expanded-access-use-in-congenital-myotonic-dystrophy-100602151",false,"NCT07119775","Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy","EXPANDED_ACCESS","This treatment plan is limited to a single patient with Congenital Myotonic Dystrophy, who is ineligible or otherwise unable to participate in ongoing clinical trials.",[28],"Congenital Myotonic Dystrophy",[11,28,30,31,32,33,34,35,36],"Myotonic Dystrophy","Dystrophia Myotonica","Myotonia Atrophica","Myotonia Dystrophica","Myotonic Dystrophy, Congenital Steinert Disease","Steinert Myotonic Dystrophy","Steinert's Disease","AVAILABLE","2025-08-06",{"date":40,"type":41},"2025-08-13","ACTUAL",{"name":5,"class":6}]